Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression.
Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. · 2023
Read Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. by Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9829236.txt.
Introduction
Guo and co-authors review how brain stimulation therapies calm neuroinflammation in anxiety and depression. Mood disorders travel with raised inflammation in the body. Symptom relief often comes with inflammation settling down. Brain stimulation is used when standard care falls short.
Results vary by person, with no firm guide for choices. The review gathers human and animal studies on the theme. It maps inflammation across the circuits tied to both disorders. Seven stimulation methods are then examined one by one. Magnetic and electric stimulation open the method list. Shock therapy, light, and ultrasound methods follow. Deep brain and vagus nerve stimulation complete the set. All were reported to dampen brain inflammation signals. Pro-inflammatory factor release fell under these treatments. The authors propose inflammation marks as treatment guides. Such marks could help match patients to methods.
Catalog record
| CREATOR | Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression By Bingqi Guo, Mengyao Zhang, Wensi Hao, Yuping Wang, Tingting Zhang, Chunyan Liu Published in: Translational Psychiatry DOI: 10.1038/s41398-022-02297-y ABSTRACT Abstract Mood disorders are associated with elevated inflammation, and the reduction of symptoms after multiple treatments is often accompanied by pro-inflammation restoration. A variety of neuromodulation techniques that regulate regional brain activities have been used to treat refractory mood disorders. However, their efficacy varies from person to person and lack reliable indicator. This review summarizes clinical and animal studies on inflammation in neural circuits related to anxiety and depression and the evidence that neuromodulation therapies regulate neuroinflammation in the treatment of neurological diseases. Neuromodulation therapies, including transcranial magnetic stimulation (TMS), transcranial electrical stimulation (TES), electroconvulsive therapy (ECT), photobiomodulation (PBM), transcranial ultrasound stimulation (TUS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS), all have been reported to attenuate neuroinflammation and reduce the release of pro-inflammatory factors, which may be one of the reasons for mood improvement. This review provides a better understanding of the effective mechanism of neuromodulation therapies and indicates that inflammatory biomarkers may serve as a reference for the assessment of pathological conditions and treatment options in anxiety and depression. Subject terms: Depression, Physiology INTRODUCTION The prevalence of anxiety and depression continues to increase. Anxiety disorders include generalized anxiety disorder, panic disorder, social anxiety disorder, agoraphobia, and specific phobias, affecting 374 million people worldwide (4802 cases per 100,000 people) [1]. Depression, characterized by low mood, slowed thinking, and reduced volitional activity, affects 221 million people worldwide (3,152.9 cases per 100,000 people) in 2020 [1]. The Lancet estimated that the coronavirus disease 2019 (COVID-19) pandemic has resulted in an additional 53.2 million cases of major depressive disorder, which led to an increase in total disability-adjusted life years (DALYs) to 49.4 million, and 76.2 million cases of anxiety disorders, with total DALYs to 44.5 million worldwide in 2020 [1]. Symptoms of anxiety and depression often coexist, and comorbidity is associated with more severe symptoms, worse quality of life, greater recurrence, and higher suicide risk than either disorder alone. Despite the increasing incidence rates and heavy burden, the treatment effect for anxiety and depression is unsatisfactory. Conventional first-line treatment, including psychotherapy and medication, only achieves a 50% remission rate [2]. Neuromodulation techniques, including TMS, TES, ECT, DBS, and VNS, as well as the promising transcranial PBM and TUS, provide important adjunctive therapies for the treatment of anxiety and depression disorders [3, 4]. The therapeutic power of neuromodulation comes from its ability to modulate the neural activity of specific brain regions and the related network function [5]. However, because of an insufficient understanding of the etiopathogenesis and pathophysiology of psychiatric disorders, even for a given symptom, the effective targets may vary from patient to patient. In addition, treatment results are generally determined by the patient’s report of symptoms, which may be lagging and unreliable. Thus, it is critical to identify objective markers to guide the formulation of treatment plans and evaluate their effectiveness. Numerous studies have confirmed the association between chronic inflammation and depression, anxiety, and other psychiatric disorders, particularly those refractory to conventional medications [6–8]. Elevated levels of peripheral inflammatory biomarkers are present in patients with depression, and the level of inflammation correlates with the severity of specific symptoms [9]. Studies using positron emission computed tomography (PET) imaging with the 18 kDa translocator protein (TSPO) as a biomarker of microglia have shown that neuroinflammation exists in multiple brain regions in depression patients [10–15] (Fig. 1). Studies using animal models have also revealed pro-inflammatory factor release and microglial activation in the brains of animals, showing signs of anxiety and depression [16–19]. Interventions using drug therapy and neuromodulation for psychiatric disorders have been shown to reduce inflammation while relieving symptoms [18, 20–27]. We hypothesized that changes in inflammatory indices could be effective indicators for neuromodulation therapy. This review examines inflammatory alterations in the brain regions involved in anxiety-related threat and fear circuits and depression-related reward circuits. Furthermore, the modulation of inflammation in these key brain areas by various neuromodulation therapies was explored, with the aim of providing a reference for basic and applied research on neuromodulation therapy for the treatment of psychiatric disorders such as anxiety and depression. [Figure: Brain regions with inflammatory activation in the key circuits of anxiety and depression.Altered inflammation in the medial prefrontal cortex (mPFC), anterior cingulate cortex (ACC), amygdala, hippocampus, insula, and other brain areas has been reported in vivo PET imaging studies in humans. The lateral habenula (LHb) and the dorsal raphe nuclei (DRN), which play an important role in depression, are found to have inflammatory changes in animal studies.] KEY NEURAL CIRCUITS AND THE BRAIN REGIONS INVOLVED IN ANXIETY AND DEPRESSION DISORDERS Decades of studies have identified the brain areas involved in the pathophysiology of anxiety and depression. Owing to the development of optogenetic and chemogenetic techniques, neural circuits can be studied at higher spatial rates through finer control of neuronal activity, and the functional complexity of brain regions and nuclei has been discovered in animals. For example, BLA projections to the PFC, hippocampus, and lateral central amygdala (CeL) have a pro-anxiety effect, while projections to the bed nucleus of the terminal striatum and medial central amygdala (CeM) have an anti-anxiety effect. Activation of the medial prefrontal cortex (mPFC)-dorsal raphe nucleus (DRN) has an antidepressant effect, while activation of the mPFC-lateral habenula (LHb) has a pro-depressant effect [28]. The subcortical projection subgroup of the DRN (represented by the projection to the CeA) promotes anxiety, and the cortical projection subgroup (represented by the projection to the prefrontal cortex) is related to reward function [29]. In parallel, studies in humans revealed the role of large-scale functional brain networks in depression and anxiety. For example, major depressive disorder (MDD) was characterized by hyperconnectivity between default network seeds and regions of the hippocampus extending to the middle temporal gyrus, and areas of mPFC. These areas are believed to support internal mentation, e.g., self-referential thinking and affective decision-making [30, 31]. INFLAMMATORY CHANGES IN THE SPECIFIC BRAIN REGIONS OF THREAT AND FEAR CIRCUITS Classically, the neural circuits closely associated with anxiety disorders are the threat-fear circuit [32], which includes the dorsolateral prefrontal cortex (DLPFC, not present in rodents), medial prefrontal cortex (mPFC, which corresponds to the medial precentral area, anterior cingulate cortex (ACC), prelimbic cortex (PL), and infralimbic cortex (IL) in rodents, with IL appearing to correspond to the subgenual cortex area, for example, [Brodmann area 25]) [33], amygdala (including the basolateral amygdala (BLA), lateral amygdala (LA), central amygdala (CeA), terminal bed nucleus), hippocampus, anterior insula, and other brain regions and nuclei. In general, external stimuli are transmitted to the amygdala and terminal bed nucleus through the thalamus and cortex. As the center of fear, the amygdala changes behaviors (freezing and startle), activate the autonomic nervous system, and transmit information to the hippocampus and bed nucleus of the terminal striatum [34]. PFC uses information gathered from various cortical and subcortical processing streams to predict the likelihood of threats in the environment, however, a persistent bias towards threat prediction can lead to a state of over-engagement in the defense system and anxiety [35]. Therefore, connections between these subcortical regions and the PFC play an